As digital transformation has become a consensus in the development of the entire society, the digital transformation of the medical industry is also deepening and taking shape. At the 6th CIIE, Zhu Lili, Vice President of AstraZeneca China and Head of Digital and Business Innovation Department, Business Strategy and Excellence Operations Department, stated in an interview with reporters that as a multinational pharmaceutical enterprise in the Chinese medical industry that has started exploring digital transformation earlier, AstraZeneca has been actively laying out digital ecological construction, innovating digital healthcare, digital education, digital operations, and digital channels in recent years.
Among them, digital healthcare mainly includes two aspects: firstly, AI can help discover drug targets earlier in research and development; The second is the innovation of integrated diagnosis and treatment. In addition to medication, patients can have better diagnosis and treatment results. For example, AstraZeneca's support for the National Standardized Metabolic Disease Management Center (MMC) created by the Shanghai Medical and Health Development Foundation is an attempt.
The digital prediction model is a very good diagnostic and therapeutic aid, such as the heart and kidney prediction model for patients with high blood pressure, hypertension, and hypertension. It is not discovered until the patient is treated, but rather by informing the risk in advance and intervening in advance, which can reduce and delay the occurrence of complications. "Zhu Lili said that on the first day of the opening ceremony of the CIIE, AstraZeneca announced a package of cooperation agreements with Jiangsu Province, including cooperation with Wuxi High tech Zone, Wuxi Big Data Group Zero Krypton Technology and Zhizhong Medical have launched strategic cooperation on Wuxi Smart City Health Big Data.
At this year's CIIE, AstraZeneca China also signed a contract with JD Health for strategic cooperation and online intelligent diagnosis of patient numbers, jointly building an online and offline linked diagnosis and treatment center. Create an online MMC in the three high fields and create a high-tech embedded breathing center in the breathing field.
In terms of channels, AstraZeneca has also spared no effort in leveraging its digital advantages. Zhu Lili introduced that grassroots business has always been a difficult area for many pharmaceutical companies to cover due to its wide distribution and low service efficiency. AstraZeneca has collaborated with multiple local e-commerce and internet healthcare platforms such as Alibaba Health to create an integrated online and offline health service scenario, enhancing the accessibility of medical and patient medication.
Based on the established standardized treatment database, AstraZeneca is also exploring empowering product research and conducting comprehensive digital medical exploration and research. For example, the company collaborated with Zero Krypton Technology to create the first national gynecological oncology research and disease management medical big data platform, Nuwa NUWA, which has been included in 22 gynecological oncology centers nationwide. Both sides will also cooperate to explore artificial intelligence assisted diagnosis and treatment, digital tumor therapy products, and promote the improvement of relevant diagnosis and treatment levels.
In addition, AstraZeneca is currently utilizing some cutting-edge digital tools to empower the entire process. AstraZeneca Zhongjin Medical Industry Fund invested company Shenrui Medical is actively promoting AI medical research. Its Dr. Wise AI medical auxiliary diagnosis system uses international cutting-edge technology to achieve advanced levels of artificial intelligence medical imaging diagnosis, which can provide clinical advice for doctors to make further diagnosis and treatment decisions.
Achieving data insight and closed-loop at every critical node is the key to the success of pharmaceutical companies' digital transformation. However, we cannot digitize for the sake of digitization. All digital transformation must be patient centered, empowering doctors and patients through digital innovation, improving the efficiency of disease management, and ultimately benefiting patients, At present, China's medical digitization is entering a stage of "favorable timing, location, and harmony". On the one hand, China has developed rapidly in fields such as artificial intelligence, effectively supporting medical digitization; On the other hand, China's large population base keeps the data volume at a large scale, which is conducive to data analysis and model building.